Gail Dutton

Gail Dutton

Gail Dutton has covered the biotech industry since soon after its inception, focusing on the intersection of business and science.

ARTICLES BY GAIL DUTTON

  • Cell Therapy Regulations Approach Their Inflection Point
    Cell Therapy Regulations Approach Their Inflection Point

    The need for discussions regarding guidelines for the development of therapeutics made from human cells, tissues, and cell- and tissue-based products has been building for a long time.

  • Biotech Bounces Back: A Tale Of Two Companies
    Biotech Bounces Back: A Tale Of Two Companies

    The fascinating stories of how Akari Therapeutics and Oncolytics Biotech each faced devastating challenges in their evolution and ultimately reinvented themselves.

  • The Common Elements Of Top-Performing Pharmas
    The Common Elements Of Top-Performing Pharmas

    Top-performing pharmaceutical companies aren’t like their peers. The top six companies have each found their own “secret sauce” that, according to a recent Accenture report, helps them dominate their markets and boost profit margins far beyond those of their peers.

  • Is Your Board Capable Of Overseeing IT?
    Is Your Board Capable Of Overseeing IT?

    Life sciences companies are at a crossroads, although they may not recognize it. Information technology is transitioning from a tool to a strategic element that contributes to business success. Most boards, however, are ill-equipped to guide this transformation.

  • The Changing Role Of The Pharma CIO
    The Changing Role Of The Pharma CIO

    "Companies that recognize the opportunities associated with digital transformation are more likely to bring in fresh blood,” Murray Aitken, executive director, IMS Institute, says.

  • Patient Services Offer Competitive Advantage For Pharma
    Patient Services Offer Competitive Advantage For Pharma

    According to “The Patient is IN: Pharma’s Growing Opportunity in Patient Services,” a recent Accenture survey of 200 patient services executives in the U.S. and Europe, 9 of the 10 most common patient services deliver above-average business impact.

  • The Business Benefits Of Revisiting Abandoned Therapies
    The Business Benefits Of Revisiting Abandoned Therapies

    DelMar Pharmaceuticals’ small molecule oncology program began with a short list of compounds that advanced to Phase 2 at the NIH but were never commercialized. By developing drugs that were in Phase 2 trials many years ago rather than creating entirely new drugs, DelMar has the benefit of beginning a program with a large body of knowledge.

  • Compassionate Use Trials Complex, But Improving
    Compassionate Use Trials Complex, But Improving

    Expanded access (compassionate use) clinical trials aren’t as straightforward as they seem, and applications to expand access for cannabinoid drug trials are even more complicated.

  • How Geographic Expansion Increases Risks In Biopharma
    How Geographic Expansion Increases Risks In Biopharma

    Risk. In the age of social media, biopharma companies have to be more careful than ever about approving or denying compassionate use of investigational drugs. There is no safe “in or out” option.

  • Building A Narrative: Develop Emotional Connections To Raise Capital
    Building A Narrative: Develop Emotional Connections To Raise Capital

    For 55 years, comedian Jerry Lewis hosted Labor Day Muscular Dystrophy Telethons featuring “Jerry’s Kids,” the poster children who made muscular dystrophy real for millions of Americans. By creating an emotional connection with the audience, those telethons raised more than $2 billion.

More From Gail Dutton